Latest Conference Articles

A fair amount of women who are diagnosed with gestational diabetes take active measures to lose weight – but what clinical outcomes does that have?

Vitamin D and diabetes have a rocky relationship, but new insight was revealed at the American Diabetes Association (ADA 2016) 76th Scientific Sessions in New Orleans, Louisiana.

What happens when a patient with type 2 diabetes uses both a potassium (K)-sparing agent and sodium-glucose co-transporter 2 (SGLT2) inhibitor at the same time?

Statistics coming from controlled trials can be challenging to apply to the real-world. But a new study assessing the use of dapagliflozin for type 2 diabetes in real clinical use yielded important insight.

New research presented at the American Diabetes Association (ADA 2016) 76th Scientific Sessions in New Orleans, Louisiana makes a case for autologous transplantation.

Pig cell transplantation could take the place of a blood glucose level-improving surgery for patients with type 1 diabetes.

It was not that long ago when doctors would sometimes not discuss the diagnosis of multiple sclerosis with their patients. Now not only is it a condition they can diagnose but treatment is also progressing by leaps and bounds.

Newly approved and longstanding treatment options are definitely an important part of the overall care picture but there is more work for a doctor to do beyond filling out a prescription pad.

As the treatment of relapsing remitting multiple sclerosis continues to add new treatment methods patients with progressive forms of the condition are still waiting for their first approved medication to manage their symptoms.

Acknowledging that uncertainty is a key factor in the care and treatment of multiple sclerosis is part of a solution to a problem, finding the best way to deal with that uncertainty is another issue that must be confronted by patients and doctors alike.

From the time a patient is diagnosed with multiple sclerosis there are often more questions than answers for extended periods of time. What that means for their care and management of symptoms is the subject of a recent study.

With a lot of the attention in multiple sclerosis care turning to finding treatments for progressive forms of the disease those who suffer relapses are in some ways being left in the shadows of treatment discoveries and care.

A recently concluded survey looked at issues most affecting patients with multiple sclerosis that they may not have been willing or able to discuss with health care providers but could help others with the condition in the future.

New medications are constantly being developed and approved for the treatment of multiple sclerosis. How those treatments are used and what the future holds for the disease remains to be seen.

There are known differences between men and women when it comes to multiple sclerosis and the likelihood of developing the disease. There are also differences in how best to treat patients given their gender.

In a chronic condition where depression is a known symptom treating the mental condition of a patient can be just as important as the physical aspects especially when suicide prevention is part of the overall care.

Defining what advanced disease means in multiple sclerosis is a topic open for discussion. Deciding a course of treatment after that determination is another challenge in overall patient care.

Even as the number of medications approved to treat relapsing remitting multiple sclerosis continues to grow patients with progressive forms of the condition still await the first approved treatment option to help manage their symptoms.

While it may not be possible to compare the efficacy of treatments for multiple sclerosis in clinical trials work is being done to look at the various options through results in actual practice.

Research into the inner workings of multiple sclerosis comes in all shapes and sizes including looking at specific parts of the brain. A recent study has looked at the role of the blood brain barrier and how it affects patients with this condition.

There are conferences held all over the world working to improve treatment of multiple sclerosis. The consortium of Multiple Sclerosis Centers is one that takes a different approach to this condition.

Individual trials have shown various benefits associated with fingolimod (Gilenya) for relapsing-remitted multiple sclerosis (RRMS), but its consistency across studies has not been fully understood.

Fingolimod (Gilenya) is an immunosuppressant used to treat multiple sclerosis, but improvements with disability have been unsteady with this drug.

Country music artist, Clay Walker – who is well-known for his hit songs “She Won’t Be Lonely Long†and “Live Until I Die" – was diagnosed with a relapsing form of multiple sclerosis (MS) at the age of 26.

“Disabled people aren’t sexually attractive†is just one real quote – and myth – from someone living with multiple sclerosis.

While newly approved treatments for multiple sclerosis move away from interferon based medications Rebif continues to be a popular choice after more than a decade in the field.

The treatment of multiple sclerosis requires the work of more than just neurologists and that figures to be the case well into the future as well.

Throughout medicine personalized care is becoming an increasing focus of the field. This is no exception for the treatment of multiple sclerosis where patients may find a medication which works for a short time before needing to find a new option.

Marijuana and alcohol – studies suggest that one of these substances helps patients with multiple sclerosis while the other can contribute to comorbidities.

Lifestyle factors and multiple sclerosis is a two-way street; but what does that mean for practicing physicians? Allen Bowling, MD, PhD, explains at the 2016 Annual Meeting of the Consortium of Multiple Sclerosis Center (CMSC) in National Harbor, Maryland.